Cent Eur J Public Health 2014, 22(3):143-146

Outcome of Antiretroviral Treatment in Patients with AIDS Monoinfection and Those Co-infected with Hepatitis B and C Viruses and Tuberculosis in Ukraine

Olga M. Radchuk1,2, Nelly P. Chentsova1, Sergii V. Tukaiev3
1 Kyiv City AIDS Centre, Kyiv, Ukraine
2 Institute of Communication and Health, University of Lugano, Lugano, Switzerland
3 Educational and Scientific Centre, Institute of Biology, National Taras Shevchenko University of Kyiv, Kyiv, Ukraine

Antiretroviral therapy reduces AIDS morbidity and mortality as well as decreases HIV transmission by reducing the viral load (VL). We aimed to determine the rate of immunological and virological failure that reflects antiretroviral treatment (ART) effectiveness among the patients of the Kyiv City AIDS Centre and may lead to ART switch in the future. In 59% of patients the prescribed ATR regimen was regarded as successful, in 37% as unsuccessful and 4% of patients were excluded for lacking sufficient follow-up time. Among the cases of unsuccessful ART, the largest part of patients was experiencing secondary immunological failure, on the second place was primary immunological failure. The temporal distribution of primary and secondary failures was also defined. It was shown that the number of patients with treatment failure increases steadily. Drug resistance testing is able to reduce the number of unsuccessful ART regimens, but such testing is not a part of the routine testing in Ukraine.

Klíčová slova: antiretroviral treatment, immunological failure, AIDS monoinfection, hepatitis, tuberculosis

Vloženo: 29. říjen 2012; Revidováno: 16. červenec 2014; Přijato: 16. červenec 2014; Zveřejněno: 1. září 2014  Zobrazit citaci

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Radchuk OM, Chentsova NP, Tukaiev SV. Outcome of Antiretroviral Treatment in Patients with AIDS Monoinfection and Those Co-infected with Hepatitis B and C Viruses and Tuberculosis in Ukraine. Cent Eur J Public Health. 2014;22(3):143-146. PubMed PMID: 25438388.
Sdílet...
Stáhnout citaci
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Zobrazit celý článek

    Reference

    1. Joint United Nations Programme on HIV/AIDS; World Health Organization. AIDS epidemic update: December 2009. Geneva: UNAIDS; 2009.
    2. Kruglov YV, Kobyshcha YV, Salyuk T, Varetska O, Shakarishvili A, SaldanhaVP.The most severe HIVepidemic in Europe: Ukraine's national HIV prevalence estimates for 2007. Sex Transm Infect. 2008 Aug;84 Suppl 1:i37-i41. Přejít k původnímu zdroji... Přejít na PubMed...
    3. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach: 2010 revision. Geneva: WHO; 2010.
    4. MEASURE Evaluation. MEASURE Evaluation in Ukraine [Internet]. Chapel Hill: MEASURE Evaluation [cited 2014Aug 6].Available from: http://www.cpc.unc.edu/measure/countries/ukraine/measure-evaluationin-ukraine.
    5. Ignorance is no longer an option: why and how to respond to the Hepatitis C epidemic in Ukraine [Internet]. Open Society Institute; 2010 [cited 2014 Feb 10].Available from http://www.harm-reduction.org/files/pdf/4country/43en_Ukraine.pdf. Přejít na PubMed...
    6. Centers for Disease Control and Prevention. Listing of countries with Hepatitis B prevalence ≥ 2% [Internet]. Atlanta: CDC; 2005 [cited 2014 Aug 6]. Available from: http://www.cdc.gov/ncidod/hepatitis/b/country_listing.htm#europe.
    7. Clavel C. Mechanisms of HIV drug resistance: a primer. PRN Notebook [Internet]. 2004 Mar [cited 2014 Aug 6];9(1):3-7. Available from: http://www.prn.org/images/pdfs/277_clavel_francois.pdf.
    8. Paredes R, Clotet B. Clinical management of HIV-1 resistance.Antiviral Res. 2010 Jan;85(1):245-65. Přejít k původnímu zdroji... Přejít na PubMed...
    9. Hirsch MS, Günthard HF, Schapiro JM, Brun-Vézinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an InternationalAIDS Society-USA panel. Clin Infect Dis. 2008 Jul 15;47(2):266-85. Přejít k původnímu zdroji... Přejít na PubMed...
    10. Forsythe S, Stover J, Bollinger L. The past, present and future of HIV, AIDS and resource allocation. BMC Public Health. 2009 Nov 18;9 Suppl 1:S4. doi: 10.1186/1471-2458-9-S1-S4. Přejít k původnímu zdroji... Přejít na PubMed...
    11. Colin L, Van Lint C. Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies. Retrovirology. 2009 Dec 4;6:111. doi: 10.1186/1742-4690-6-111. Přejít k původnímu zdroji... Přejít na PubMed...
    12. Kuritzkes DR. HIV resistance: frequency, testing, mechanisms. Top HIV Med. 2007 Nov-Dec;15(5):150-4.
    13. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, et al. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS. 2007 Jan 11;21(2):215-23. Přejít k původnímu zdroji... Přejít na PubMed...
    14. ART failure and strategies for switching ART regimens in the WHO European Region: report of the WHO expert consultation, Copenhagen, 7 December 2007. Copenhagen: WHO Regional Office for Europe; 2008.
    15. Ministry of Health of Ukraine. Clinical protocol of ARV therapy for HIV-infected adults and adolescents. Kiev: Ministry of Health of Ukraine; 2010. (In Ukrainian.)
    16. Eramova I, Matic S, Munz M, editors. HIV/AIDS treatment and care: clinical protocols for the WHO European Region. Copenhagen: WHO; 2007.
    17. Bilgin M, Balci NC, Erdogan A, Momtahen AJ, Alkaade S, Rau WS. Hepatobiliary and pancreatic MRI and MRCP findings in patients with HIV infection. AJR Am J Roentgenol. 2008 Jul;191(1):228-32. Přejít k původnímu zdroji... Přejít na PubMed...
    18. Anderson KB, Guest JL, Rimland D. Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 2004 Nov 15;39(10):1507-13. Přejít k původnímu zdroji... Přejít na PubMed...
    19. Miller MF, Haley C, Koziel MJ, Rowley CF. Impact of hepatitis C virus on immune restoration in HIV-infected patients who start highly active antiretroviral therapy: a meta-analysis. Clin Infect Dis. 2005 Sep 1;41(5):713-20. Přejít k původnímu zdroji... Přejít na PubMed...
    20. Yacisin K, Maida I, Ríos MJ, Soriano V, Núñez M. Hepatitis C virus coinfection does not affect CD4 restoration in HIV-infected patients after initiation of antiretroviral therapy. AIDS Res Hum Retroviruses. 2008 Jul;24(7):935-40. Přejít k původnímu zdroji... Přejít na PubMed...
    21. Antonello VS,Appel-da-Silva MC, Kliemann DA, Santos BR, Tovo CV. Immune restoration in human immunodeficiency virus and hepatitis C virus coinfected patients after highly active antiretroviral therapy. Braz J Infect Dis. 2013 Sep-Oct;17(5):551-4. Přejít k původnímu zdroji... Přejít na PubMed...
    22. Ukraine: national report on monitoring progress towards the UNGASS Declaration of Commitment on HIV/AIDS. Reporting period: January 2006 - December 2007. Kyiv: Ministry of Health of Ukraine; 2008.
    23. Bennett DE, Bertagnolio S, Sutherland D, Gilks CF. The World Health Organization's global strategy for prevention and assessment of HIV drug resistance. Antivir Ther. 2008;13 Suppl 2:1-13. Přejít k původnímu zdroji...

    Zpět na obsah